Amicus Therapeutics to Present at Robert W. Baird & Co. 2016 Healthcare Conference

CRANBURY, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Robert W. Baird & Co. 2016 Healthcare Conference in New York, NY on Wednesday, September 7 at 3:10pm ET.

An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.

About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.

FOLD–G

CONTACTS:

Investors/Media:
Amicus Therapeutics
Sara Pellegrino
Senior Director, Investor Relations
[email protected]
(609) 662-5044

Media:
MWW PR
Sean Conley
[email protected]
(646) 381-9096

Source: Amicus Therapeutics, Inc

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amicus Therapeutics (FOLD) PT Lowered to $14 at BofA Securities
• Ameriprise Financial Motivates and Empowers Women at Its 7th Annual Women Advisor Summits
• Streaming Video Technology Alliance Launches Comprehensive Set of Specifications for Configuration Interface